Review

Highlighting the Relevance of Gut Microbiota Manipulation in Inflammatory Bowel Disease

Flavia Maria Pavel 1, Cosmin Mihaei Vesa 1,† ⋆, Gina Gheorghe 2,3,†, Camelia C. Diaconu 2,3,†, Manuela Stoicescu 4, Mihai Alexandru Munteanu 4, Elena Emilia Babes 4, Delia Mirela Tit 5,6,†, Mirela Marioara Toma 5,6 and Simona Bungau 5,6,†

1 Department of Preclinical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania; flavia.bontze@gmail.com (F.M.P.); v.cosmin_15@yahoo.com (C.M.V.)
2 Department 5, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania; ghgeorghe_gina2000@yahoo.com (G.G.); drcameliadiaconu@gmail.com (C.C.D.)
3 Department of Internal Medicine, Clinical Emergency Hospital of Bucharest, 105402 Bucharest, Romania
4 Department of Medical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410041 Oradea, Romania; manuela_stoicescu@yahoo.com (M.S.); mihaimunteanual@yahoo.com (M.A.M.); eebabes@uoradea.ro (E.E.B.)
5 Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, 410028 Oradea, Romania; mirela_tit@yahoo.com (D.M.T.); mire.toma@yahoo.com (M.M.T.)
6 Doctoral School of Biological and Biomedical Sciences, University of Oradea, 410087 Oradea, Romania

† These authors contributed equally to this work.

Abstract: Two different conditions are included in inflammatory bowel disease (IBD), Crohn’s disease (CD) and ulcerative colitis (UC), being distinguished by chronic recurrence of gut inflammation in persons that are genetically predisposed and subjected to environmental causative factors. The normal structure of the gut microbiome and its alterations in IBD were defined in several microbial studies. An important factor in the prolonged inflammatory process in IBD is the impaired microbiome or “dysbiosis”. Thus, gut microbiome management is likely to be an objective in IBD treatment. In this review, we analyzed the existing data regarding the pathophysiological/therapeutic implications of intestinal microflora in the development and evolution of IBD. Furthermore, the main effects generated by the administration of probiotics, prebiotics, fecal transplantation, and phytochemicals supplementation were analyzed regarding their potential roles in improving the clinical and biochemical status of patients suffering from Crohn’s disease (CD) and ulcerative colitis (UC), and are depicted in the sections/subsections of the present paper. Data from the literature give evidence in support of probiotic and prebiotic therapy, showing effects such as improving remission rate, improving macroscopic and microscopic aspects of IBD, reducing the pro-inflammatory cytokines and interleukins, and improving the disease activity index. Therefore, the additional benefits of these therapies should not be ignored as adjuvants to medical therapy.

Keywords: gut microbiota; supplements; inflammatory bowel disease; Crohn’s disease; ulcerative colitis; probiotics; prebiotics; fecal microbiota transplant; phytochemicals

1. Introduction

Inflammatory bowel diseases (IBD) are chronic, immune-mediated conditions, which affect the gastrointestinal tract. The term IBD includes Crohn’s disease (CD) and ulcerative colitis (UC), which both present an elaborate etiology and pathogenesis that has been insufficiently described and acknowledged. IBD occurrence has become more frequent over time, this being connected to industrial progress and innovation and related lifestyle changes. The prevalence of these diseases is higher in developed countries, where it can reach up to 4 cases per 1000 inhabitants [1]. From an epidemiological point of view, the incidence of IBD varies by two criteria, that is, geographical region and age. Thus, in the North American...
The incidence of UC varies between 2.2 and 19.2 cases per 100,000 inhabitants, and the incidence of CD between 3.1 and 20.2 per 200,000 inhabitants [2]. According to age, there is a bimodal distribution of IBD, with a first peak between 15 and 30 years, and the second peak after 60 years [2]. If approximately 25% of patients develop IBD in adolescence, 10–15% of them may have IBD onset after the age of 60 years [2].

Currently, the exact pathophysiological mechanism leading to IBD is not known, one of the hypotheses being the existence of an aggressive immune response to the intestinal microbiota in genetically predisposed individuals. This hypothesis is supported by recent studies that have identified susceptibility loci at or near genes involved in the innate or adaptive immune response to various germs [2–5]. However, there are numerous studies aimed at identifying non-immunosuppressive therapeutic agents with a possible benefit for patients with these conditions. These agents target microbial flora disorders that accompany IBD and include prebiotics, probiotics, antibiotics, or fecal microbial transplantation. Unfortunately, these studies have failed to demonstrate a definite benefit of drugs targeting the intestinal microflora and, as a result, have not been approved in current therapeutic guidelines.

The main two entities that are part of IBD, CD and UC, are differentiated by the location of the lesions and the layers of the digestive tract wall involved. Thus, CD is characterized by the involvement of all the digestive tract layers, otherwise known as transmural damage, which can induce inflammation, strictures, or even fistulas. In the advanced stages, the mucosa acquires the appearance of cobblestone by the presence of linear ulcerations alternating with areas of normal mucosa [2–4]. CD lesions can be present in any segment of the digestive tract. The ileum and colon are most frequently affected, the gastroduodenal segments being involved in only 5% of cases [4]. The upper gastrointestinal tract may be more commonly involved in childhood CD forms [4]. Typically, the rectum is spared in CD, but anorectal complications (fistulas and abscesses) are common [2,4]. UC, unlike CD, is characterized by diffuse inflammation in the colonic mucosa, most commonly affecting the rectum (proctitis). However, UC lesions may extend to the sigmoid (proctosigmoiditis), beyond the sigmoid (distal ulcerative colitis), or may include the entire colon (pancolitis) [2]. The two diseases can be classified depending on the extension into mild, moderate, and severe forms, and depending on the location [2]. Additionally, for CD, there is a phenotypic classification into inflammatory, structuring, or penetrating forms [2]. Both patients with CD and those with UC can associate extraintestinal manifestations that may involve the eyes, skin, and bones, such as arthritis, ankylosing spondylitis, uveitis, aphthous stomatitis, or erythema nodosum [4].

This article centralizes the existing data provided by significant literature published between 1989 and 2021 and related to the pathophysiological and therapeutic implications of intestinal microflora in the development and evolution of IBD; moreover, it presents in detail the beneficial effects of probiotics, prebiotics, phytochemicals supplementation, or fecal transplant in improving the clinical parameters of IBD patients. In this regard, the authors searched the most well-known databases (i.e., MDPI, Scopus, ScienceDirect, Elsevier, Frontiers, etc.), using key words or combinations of them (i.e., gut microbiota; supplements; inflammatory bowel disease; Crohn’s disease; ulcerative colitis; probiotics; prebiotics; fecal microbiota transplant; phytochemicals, etc.). As a result, 172 references were cited as supporting the statements in this work.

Moreover, the present research intends to provide specialists and patients with new information related to this topic and to make as accessible as possible the published data regarding the newest/latest therapies in the field; in addition, the most pertinent and relevant results obtained in medical practice were registered, focused on the optimization of the management of this pathology, both by examining the valuable scientific evidences and by presenting/respectively evaluating the modern ways of treating this disease.
2. Gut Microbiota in the Pathogenesis of IBD

There are currently numerous studies that have investigated the relationship between intestinal microflora and IBD [3]. These studies have demonstrated the essential role that the microbiome plays in the development and evolution of intestinal inflammation [3,6]. According to existing data already published, the intestinal microflora of patients with IBD present an increase in the number of bacteria from the *Proteobacteria* phylum family and a decrease in those from the *Firmicutes* phylum and *Bacteroides* families, compared to normal individuals [4,7–10]. In addition, the diversity of bacterial microflora, known as α diversity, is lower in patients with intestinal inflammation [4,11,12]. Patients with CD show a reduction in α diversity in fecal microbiomes, a change also identified among monozygotic twins [11,12]. This dysbiosis has been associated with the instability of microbial species dominance in IBD [13]. There are data that show a reduction in microbial diversity in tissues with inflammatory changes, compared to those without inflammatory changes, even in the same patient [14]. A similar dysbiosis was observed in patients with colitis secondary to *Clostridium difficile* infection, suggesting the possibility of using treatments for this infectious disease in patients with IBD [4,15].

A multicenter study that looked at more than 1000 fecal samples from children with CD has found an increase in the number of species from the *Veillonellaceae*, *Pasteurellaceae*, and *Enterobacteriaceae* families, and a decrease in those from the *Bacteroidales*, *Erysipelotrichales*, and *Clostridioides* families [16]. These changes have also been associated with disease status [16]. Another important observation of this study is the possibility of using the microbial profile of the rectal mucosa as a biomarker for the diagnosis of CD in its early stages [16].

From the patho-physiological point of view, the association of intestinal dysbiosis with the appearance of inflammatory changes can be explained by the increase in the number of bacteria with a proinflammatory role and the reduction of those with an anti-inflammatory role, compared to healthy individuals [9,10]. For example, *Faecalibacterium prausnitzii*, which is part of the Clostridium IV family, has demonstrated an anti-inflammatory role due to its production of butyrate. In patients with CD, there is a reduction in the number of bacteria from the *Faecalibacterium prausnitzii* family, a reduction that has been correlated with the risk of relapse after surgical treatment among these patients [17,18]. Additionally, a reduction in the number of *Blautia faecis*, *Roseburia inulinivorans*, *Ruminococcus torques*, and *Clostridium lavalense* has been demonstrated in patients with CD [17,18]. In UC, during the remission period, changes in the colonization of *Faecalibacterium prausnitzii* were observed, and the restoration of the population of this bacterial species after relapse is associated with the maintenance of clinical remission. An important role of *Faecalibacterium prausnitzii* has been demonstrated by Sokol et al. They showed that the stimulation of peripheral blood mononuclear cells by this bacterium inhibits the production of inflammatory cytokines (IL-12, interferon gamma) and stimulates the production of IL-10 with an anti-inflammatory role [19,20]. In patients with hereditary risk of IBD, a reduction of *Roseburia* spp. was observed in the intestinal microbiome [19,20].

The above data have been supported by other studies that have shown an increase in the number of species from the *Proteobacteria* family, especially *Escherichia coli*, in the intestinal mucosa of patients with CD. Among the serotypes of *Escherichia coli*, the one isolated from the intestinal mucosa of adults with CD is adhesion-invasive *E. coli* (AIEC) [21,22]. An increase in the number of AIECs was reported in 38% of patients with CD, compared with 6% of healthy patients [23,24]. These pathogenic bacteria have the ability to adhere to the intestinal epithelium, to alter intestinal permeability, and to induce intestinal inflammation by regulating the expression of inflammatory genes [21–24]. According to El Ashmar et al., exposure of intestinal epithelium not only to pathogens but also to commensal bacteria could lead to increased intestinal permeability (host-dependent zonulin secretion causes the impairment of the small intestine barrier function after bacterial exposure) [25]. Moreover, Arietta et al. confirmed that this alteration was associated with the development of colitis (reducing low intestinal permeability results in attenuated
Altered gut bacteria implication in the pathogenesis of IBD is summarized in Figure 1.

Another pathophysiological hypothesis incriminated in the development of IBD is the impairment of the production of metabolites by intestinal dysbiosis. An example is the decrease in the concentration of short-chain fatty acids (SCFAs) secondary to the production of butyrate by Faecalibacterium prausnitzii or other species from Clostridium clusters IV, XIVa, or XVIII [18]. The consequence of this decrease in SCFAs is the alteration of regulatory T-cell differentiation and expression, and thus the growth of epithelial cells and the maintenance of intestinal homeostasis [28,29].

Besides the bacteria from the Enterobacteriaceae family, another class of adherent and invasive bacteria in the mucosa of the digestive tract with a role in the development of IBD are those from the Fusobacteria family [29–32]. Fusobacterium species mainly colonize the oral cavity and intestine and have been shown to be abundant in the colonic mucosa of patients with UC [32]. An experiment in mice has shown that the administration of Fusobacterium varium by rectal enema leads to inflammatory changes in the colonic mucosa. In humans, the bacterium Fusobacterium has been implicated in the pathophysiology of IBD and correlated with the severity of IBD. Another very important role of the Fusobacterium species is its involvement in tumorigenesis. Thus, there are experimental data in mice which claim that these bacterial species are present in greater numbers in a colorectal tumor than in the normal adjacent tissue [33,34]. In the intestinal microflora there are bacteria with a protective role against IBD, such as Lactobacillus, Bifidobacterium, and Faecalibacterium. Their protective role is explained by the stimulation of the production of anti-inflammatory cytokines (like IL-10) and reduction of the production of inflammatory cytokines [35]. Ileal biopsies from CD patients have shown a reduction in the populations of Faecalibacterium prausnitzii (which have an anti-inflammatory role), and an increase in the populations of E. coli [20,36]. Another bacterium with a possible protective role against the development of IBD has been shown to be Helicobacter pylori [20,37]. Altered gut bacteria implication in the pathogenesis of IBD is summarized in Figure 1.

Figure 1. Altered gut bacteria implication in the pathogenesis of IBD.
3. Probiotics Effects in IBD

Probiotics are microorganisms capable of surviving in the acidic gastric environment. To this point, the existing data support the beneficial role of probiotics in the treatment of IBD [38,39].

The following mechanisms have been suggested for the action of probiotics: stimulation of anti-inflammatory cytokines production (IL-10, transforming growth factor beta (TGF β)), antimicrobial substances secretion, suppression of bacterial growths (thus antimicrobial role), induction of an immune response, immunomodulatory role, improvement of the epithelial barrier function, and suppression of T-cells proliferation [40–43].

In order for the microorganisms to be considered probiotic agents, they have to meet certain conditions:

- To survive in the pancreatic, biliary, and gastric acidic secretions, and thus to be viable when they reach the small and large intestines;
- To remain viable during transportation and storing;
- To lack toxic or other pathogenic effects on normal human structures;
- To have beneficial effects for the host;
- To adhere to the intestinal epithelial cells;
- To stabilize the intestinal microbiota;
- To produce antimicrobial substances.

Intestinal microbiota have a series of beneficial effects on the normal development of the human organism, but disturbing the homeostasis between the gut bacteria and the immune response can lead to inflammatory changes [44–46].

The interaction between probiotic agents and intestinal epithelial cells leads to a decrease in the response of various pro-inflammatory stimuli [47]. This reaction can be explained by the inhibition of the degradation of the nuclear factor kB (IkB/NF-kB) and also by the inhibition of the IkB/NF-kB pathway. Thus, nuclear translocation of NF-kB and the corresponding gene expression are prevented [48].

There is a study that used lining samples from CD patients to observe the existing differences between epithelial cells cultures with no probiotics and those treated with probiotic agents, such as non-pathogen E. coli species, Lactobacillus casei DN-114001, Lactobacillus bulgaricus LB10, and Lactobacillus crispatus, after 24 h. The following differences were detected: TNF-alpha release from the epithelial cells was significantly reduced in the cultures treated with Lactobacillus casei DN-114001 and Lactobacillus bulgaricus, in opposition to the ones treated with Lactobacillus crispatus and E. coli, where no important changes were noticed. In addition, in the cultures treated with Lactobacillus casei DN-114001 and Lactobacillus bulgaricus, besides the TNF-alpha expression reduction in intraepithelial lymphocytes, a decrease of CD4 cells number could be noticed. Probiotics interact with immunocompetent cells by modulating pro-inflammatory cytokines’ local production. The immune system mediators that are responsible for recognizing pathogenic agents are the toll-like receptors (TLRs) [49].

Summarizing the existing information so far, the main immune effects of this microorganism are as follows:

- Reduction of the activity of nuclear factor kappa B (NF-kB);
- Increase of the activity of natural killer cells (NK);
- Involvement in the maturation of dendritic cells;
- Stimulation of cytokines (IL 10) production;
- Activation of antigen presenting cells found in Peyer’s plaques [50–54].

3.1. Crohn’s Disease

Most studies that have evaluated the role of probiotic agents in CD have demonstrated their effectiveness in maintaining the clinical remission of the disease.

A study conducted in 2000 showed that Saccharomyces boulardii combined with mesalazine reduce the recurrence rates in adults with CD [55]. Another study, conducted in 2013, com-
pared two groups of patients: one group who underwent basic therapy with *Saccharomyces boulardii* and another group who combined this with a placebo [56]. However, this study did not demonstrate significant efficacy of *Saccharomyces boulardii* compared to placebo, in terms of IBD recurrence rate (47.5% vs. 53.2%) [56].

An experiment in mice showed that supplementation with *Saccharomyces boulardii* leads to reduced intestinal permeability and secondary bacterial translocation. However, an immunomodulatory effect of this microorganism has been demonstrated, by increasing plasma levels of IL-10 and intestinal IgA secretion [57].

Another study of patients with CD showed a beneficial effect of using “Synergy 1”, a product containing *Bifidobacterium longum*, oligofructose, and inulin. The administration of this product for a period of six months led to the reduction of proinflammatory biomarkers such as TNF-α in the intestinal mucosa, reduction of the disease activity index, and also improvement of histological parameters [58].

Fedorak et al. evaluated in 2015 the efficacy of another probiotic agent, VSL#3 (containing *Bifidobacterium infantis*, *Bifidobacterium breve*, *Bifidobacterium longum*, *Streptococcus thermophilus*, *Lactobacillus paracasei*, *Lactobacillus acidophilus*, *Lactobacillus reuteri*, in L) in patients with CD undergoing surgical treatment (intestinal resection). Two groups were formed: the first group consisted of patients with CD who received VSL#3 immediately after surgery and maintained this treatment for a period of 365 days; the second group consisted of patients who received VSL#3 for a period of 275 days (from day 90 after surgery until day 365). Ninety days post-operatively, the two groups—the first of which had already been treated with VSL#3 for 90 days, while group 2 had not yet received VSL#3—underwent endoscopic investigation. However, this evaluation did not show significant differences between the two in terms of intestinal lesions. The second evaluation was performed at 365 days, at the end of the study. According to this evaluation, group 1, who received VSL#3 immediately after surgery, had a lower level of pro-inflammatory cytokines (IL-8 and IL-1β) in the intestinal mucosa and a lower rate of recurrence compared to group 2, in whom VSL#3 treatment was initiated 90 days after surgery. In conclusion, this study proved that the administration of probiotics in patients with CD is more effective if initiated immediately after surgery, compared to late initiation [59].

Two other studies evaluated the role of probiotic agents in inducing remission in patients with CD, demonstrating an improvement in the CDAI score among patients who received these microorganisms. However, these studies used different preparations and observed, in total, only 14 patients. The first study evaluated the efficacy of *Lactobacillus* and *Bifidobacterium*. The second study initially included 11 patients who were randomized into two groups: the first group received a placebo agent, and the second group received *Lactobacillus rhamnosus* GG in combination with antibiotics and steroids, over a period of one week. Of these, only five patients reached the end of the study and no additional benefits of *Lactobacillus rhamnosus* GG were shown compared to placebo [60,61]. *Lactobacillus rhamnosus* GG has also been evaluated in children with DCI but has not shown additional benefit over placebo [62,63].

Other studies have evaluated the effectiveness of *Lactobacillus johnsonii* and *E. coli Nissle* in maintaining IBD remission, but without showing significant benefit [64].

Current data suggest that the concomitant use of multiple microorganisms in patients with IBD leads to better results on disease progression than the use of a single microorganism. The most effective have been the microorganisms in the families *Bifidobacterium* and *Saccharomyces boulardii*. The determination of the optimal dose represents another problem regarding the use of probiotics in IBD. Many studies use higher than recommended doses, while other studies do not specify the dose used. Two special categories of patients are children and elderly patients, the data on the use of probiotics in IBD in these categories being much more limited. Thus, we need further studies to monitor the effective use of probiotics in IBD among these patients [65].
3.2. Ulcerative Colitis

The effectiveness of combining probiotic agents with standard therapies has been evaluated in numerous studies and among patients with UC. One study, which included 244 patients with mild or moderate forms of UC, looked at the benefits of combining *Saccharomices boulardii* and VSL#3 with conventional therapy. According to this study, the products mentioned above did not significantly contribute to the improvement of the remission rates of the disease, but they proved a benefit in reducing disease activity [66]. Nevertheless, other studies have evaluated the effectiveness of VSL#3 in UC, with more promising results. Sood et al. demonstrated that combining VSL#3 with standard therapy over a 12-week period improves disease remission rates by reducing ulcerative colitis disease activity index (UCDAI) score by more than 50%. Another important conclusion was the improvement of lesions from the level of the colonic mucosa at the endoscopic evaluation in the group of patients who used VSL#3 [67].

The effectiveness of VSL#3 has also been proven among children with UC. Thus, a study that followed 29 children with UC over a 1-year period showed a significant improvement in the remission rate of the disease by combining VSL#3 with 5-aminosalicylic acid (5-ASA) and steroids therapy, compared with patients who combined placebo agents with this standard therapy (93% vs. 61%) [68]. Another study that looked at 18 children with UC reported both an improvement in histological scores and a reduction in the level of inflammatory markers by combining VSL#3 with standard therapy [69].

Another probiotic agent that has been shown to be effective in improving endoscopic and histological scores in patients with UC is bifidobacteria-fermented milk (a combination of *Bifidobacterium strains* and *Lactobacillus acidophilus*) [70]. It is worth mentioning that the concentration of SCFAs in feces is increased in the case of the probiotic-treated group vs. a placebo group. However, a more recent study on 195 patients, describing a similar strategy of treatment (which included fermented milk containing *B. breve* + *L. acidophilus*), demonstrated no efficacy to cure or at least to maintain the UC remission [71]. In healthy volunteers, from a practical point of view, *B. bifidum* usage as single-strain-containing probiotic has been shown to be sufficient to enhance SCFAs levels in feces [72]. Taking into account all these data, however, the probiotic’s protective role in both UC and/or CD remains insufficiently known.

Despite some discrepancies regarding the number of patients used in the studies mentioned above, the first study was the only one to confirm the increased number of Bifidobacteria in the feces of probiotics-treated patients and to perform endoscopic analysis. In the literature there is, however, data suggesting that the use of certain microorganisms may even negatively influence the evolution of patients with IBD. For example, a Danish study comparatively followed two groups of patients with UC over a period of 7 weeks: the first group underwent the standard therapy of *E. coli* with foreign Nissle, and the second group, a placebo agent. The result was that the group of patients taking probiotic therapy had a higher dropout rate and an even lower rate of clinical remission. The hypothesis of the unfavorable effect of *E. coli Nissle* on the evolution of IBD is supported [73]. On the other hand, the rectal administration of Escherichia coli Nissle for proctitis or proctosigmoiditis did not demonstrate additional benefits over placebo [74].

Regarding rectally administered probiotic products, *Lactobacillus reuteri ATCC 55730* in combination with mesalamine has shown benefits in ameliorating mild to moderate forms of UC in children. The study which evaluated this biological compound looked at two groups of pediatric patients with mild or moderate forms of UC; the first group combined *Lactobacillus reuteri ATCC 55730* with standard mesalamine therapy, and the second group combined placebo with mesalamine. At the end of the study, patients in the first group had both a better clinical response, objectified by reducing the Mayo Disease Activity Index (MDAI) by ≥2 compared to group 2 (100% vs. 53%), and a better remission rate, objectified by an MDAI score of <2.0 (31% vs. 0%) [75].
Among patients with mild to moderate forms of UC, a number of studies have compared the effectiveness of using probiotic agents with standard 5-ASA therapy. The probiotic agents evaluated were *Escherichia coli Nissle 1917*, *Bifidobacterium breve strain Yakult*, *Bifidobacterium breve*, and *Saccharomyces boulardii*. These studies concluded that the probiotic agents mentioned above have a similar efficacy to 5-ASA in maintaining clinical and histological remission in patients with mild to moderate forms of UC [76–79].

An important therapeutic target in the management of patients with IBD is the prevention of early relapses [80]. Thus, in 2010, a small study, which followed six patients with UC in remission, reported that maintenance treatment with 400 mg rifaximin and 500 mg *Saccharomyces boulardii* led to the maintenance of clinical remission after three months of use. The conclusion was that this therapeutic combination might be useful in preventing early relapses in UC [81].

The main effects of different probiotics in IBD are summarized in Figure 2 [79,82–85]. Dose, treatment duration, and efficiency of probiotic in UC and Crohn’s disease are presented in Table 1.

![Figure 2. Effects of different probiotics in IBD.](image-url)
Table 1. Dose, duration of treatment, and efficiency of probiotic in ulcerative colitis and Crohn’s disease.

| Probiotic                                      | Ulcerative Colitis                                      | Crohn’s Disease                                      | Ref. |
|------------------------------------------------|---------------------------------------------------------|------------------------------------------------------|------|
| **Dose of Probiotic; Duration of Treatment; Probiotic Effect** | **Dose of Probiotic; Duration of Treatment; Probiotic Effect** | **Dose of Probiotic; Duration of Treatment; Probiotic Effect** |      |
| *Escherichia coli*                              | 25 × 10⁹ CFU/100 mg; 12 weeks; remission period similar with groups treated with standard therapy | 10⁹ CFU/day; 1 year; improvement of drug adherence and reduction of recurrence rate | [77,86] |
| *Escherichia coli* NISSLE 1917.                 | 10⁸/mL—10, 20, 40 mL; 2 weeks; improvement of macroscopic and microscopic parameters | -                                                   | [74] |
| *Saccharomyces boulardii*                       | 250 mg × 3/day; 4 weeks; improvement of remission rate | 1 g/day; 6 months; improvement of remission rate    | [55,87] |
| *Bifidobacterium infantis,* *Bifidobacterium longum,* *Streptococcus thermophilus,* *Lactobacillus casei,* *Lactobacillus plantarum,* *Lactobacillus acidophilus,* and *Lactobacillus delbrueckii* | 450–18 × 10⁹ CFU/day; 1 year; improvement of remission rate; improvement of macroscopic and microscopic parameters | 9 × 10¹¹ CFU × 2/day; 1 year; improvement of remission rate and reduction of intestinal pro-inflammatory cytokines | [59,68] |
| *Bifidobacterium longum* (BL) and Inulin-oligofructose (IOf) | 2 × 10¹¹ CFU BL + 6 g IOf × 2/day; 4 weeks; reduction of inflammatory markers | -                                                   | [88] |
| *Bifidobacterium longum*                        | 2–3 × 10¹¹ CFU/day; 8 weeks; improvement of remission rate | 2 × 10¹¹ CFU/day; 6 months; reduction of intestinal pro-inflammatory cytokines, improvement of microscopic parameters, improvement of disease activity index | [89] |
| *Bifidobacterium breve* (BB) and galacto-oligosaccharide (GoS) | 10⁹ CFU × 3/day BB + 5.5 g/day GoS; 1 year; reduction of fecal pH, fecal *Bacteroidaceae,* and myeloperoxidase | -                                                   | [90] |
| *Bifidobacterium breve* (BB), *Bifidobacterium longum* (BL), *Lactobacillus casei* (LC), *Psyllium* (P) | -                                                      | 30 × 10⁹ CFU/day BB, 15 × 10⁹ CFU/day BL, 30 × 10⁹ CFU/day LC9.9 g/day P; 8.5–18 weeks; improvement of clinical parameters | [61] |
| *Lactobacillus rhamnosus* GG                   | 18 × 10⁹ CFU/day; 12 months; improvement of remission rate | 10¹⁰ CFU × 2/day; 6 months; improvement of disease activity index, reduction of intestinal permeability | [60,91] |
| *Lactobacillus delbrueckii* and *Lactobacillus fermentatium* | -                                                      | -                                                   | [92] |
| *Lactobacillus salivarius,* *Lactobacillus acidophilus* and *Bifidobacterium strain BGN4* | -                                                      | -                                                   | [93] |

Legend: CFU—colony-forming units.

4. Prebiotics

The current therapeutic management of patients with IBD aims, in addition to obtaining clinical and histological remission, to identify alternative methods that lead to the reduction of costs and toxicity involved in immunosuppressive therapies. Prebiotics are non-absorbed carbohydrate polymers, as opposed to probiotics, which are living microorganisms. Prebiotics include fructo-oligosaccharides, inulin, and galacto-oligosaccharides, compounds that stimulate the growth and metabolic activity of beneficial bacteria that
are part of the intestinal microflora, such as Bifidobacterium and Lactobacillus species. Another important action of prebiotics is to stimulate the bacterial production of short-chain fatty acids, such as butyrate, with immunoregulatory effects. These effects include histone deacetylase and PPARγ activities with activation of regulatory T cells via G protein receptor 43 and GPR109a and inhibition of pro-inflammatory cytokines [94–96]. On the other hand, butyrate is also a metabolic fuel for colon epithelial cells. Numerous experimental studies have demonstrated the effectiveness of oral use of prebiotics alone or in combination with probiotic agents (symbiotics). However, data on the efficacy of these therapeutic preparations in IBD in humans is limited [97,98].

In CD, the use of prebiotics did not show a significant improvement in the evolution of these patients. A study looked at the effectiveness of taking fructo-oligosaccharides in patients with active CD over a period of four weeks. The authors concluded that therapeutic supplementation with this prebiotic agent does not improve the remission rate of CD [99]. However, the combined administration of a prebiotic agent with Bifidobacterium longum in patients with active CD showed both an improvement in clinical and histological scores and a reduction in the concentration of TNFα in the mucosa [100]. In addition, the association of some probiotics with psyllium fiber in steroid refractory CD patients led to 60% remission rates [61]. Another study, however, followed patients with CD who underwent surgical treatment and showed that the combination of four prebiotic agents with four probiotic agents does not bring benefits in preventing postoperative recurrence of this condition [101].

Therapeutic supplementation with oligofructose-enriched inulin does not influence the remission rate of the disease in patients with UC but leads to reduced fecal levels of calprotectin [100]. Inulin is another therapeutic agent that has been shown to improve histological lesions in patients with pouchitis, without improving clinical parameters is [102].

The main action that fructans have on the GI system is the modulation of the intestinal microflora. Numerous studies highlighted the favorable effect of inulin inside the intestine (by acting on the *F. prausnitzii* and *Anaerostipes* sp. levels); this partly explains some of the butyrogenic effects of inulin intake [103–105]. It was demonstrated as well that fructo-oligosaccharide (FOS) and galacto-oligosaccharide (GOS) improve the levels of *F. prausnitzii* [106].

In dose–response trials of FOS supplementation, the minimum prebiotics dose capable to induce a bifidogenic effect in healthy subjects was considered 10 g/day, while the dose is decreased (2.5–5 g/day) for inulin-type prebiotics [107–109].

Actually, it has been demonstrated that at least two weeks of having vegetables rich in inulin-type fructans in one’s diet results in a 3.8-fold Bifidobacterium genus increase; furthermore, an increase in B. longum subsp. longum was induced (at the species level), and a decrease in the cases of *B. bifidum*, *B. pseudocatenulatum*, and *B. adolescentis* [22,110]. All these data confirm previously published results, which certify that Jerusalem artichoke (which is rich in inulin) intake was correlated to Bifidobacterium increasing [44,47,111,112].

More recent studies have demonstrated that fructans are also able to provide antioxidant actions (higher than in the cases of glucose, fructose, and sucrose) [2], suggesting in this regard that the antioxidant effect is characteristic of FOS. The presence of branches in the molecules and/or the DP influence and induce the antioxidant action of fructans; in this regard, the highest antioxidant-type effects are associated with the branched fructans (agavins) and the linear fructans with a low DP (e.g., inulin Frutafit IQ®) [43]. Articles on the topic have proven that the antioxidant capacity of inulin IQ resists during the cooking process, and, respectively, during digestion. Therefore, these observations make even more interesting the rather unstable antioxidant characteristic of fructans (these being known as some of the main water-soluble antioxidants). It is also speculated that inulin-type fructans have the ability to act indirectly, eliminating reactive oxygen species (ROS) (due to the action of SCFA resulting from their fermentation in the colon), and potentiate the activity of antioxidant enzymes glutathione S-transferase (GST) [113].
All the studies above demonstrate a beneficial potential of prebiotics (as they are depicted in Figure 3) [114–125] in the therapeutic management of IBD, but they have a number of limitations. Thus, future studies are needed to elucidate the pathophysiological mechanisms and therapeutic effects of prebiotics.

**Figure 3. Beneficial effects of prebiotics.**

5. Fecal Microbiota Transplant (FMT)

FMT is currently a potential therapeutic option in patients with a disturbed gut ecosystem. FMT can lead to increased production of short-chain fatty acids, such as butyrate, improving the integrity of the intestinal barrier and thus reducing bowel permeability and severity of IBD. On the other hand, FMT can contribute to the following: the correction of intestinal dysbiosis by inhibiting both T-cell activity and also leukocyte adhesion and the synthesis of pro-inflammatory factors [126]; decreasing colonic inflammation; and initiating intestinal homeostasis restoration by cumulative activation of various immune-mediated pathways [127].

As a procedure, FMT involves harvesting feces from a healthy donor and transplanting them into the patient’s gastrointestinal tract. This therapeutic method has proven to be over 90% effective among patients with recurrent *Clostridium difficile* infection, resistant to standard antibiotic treatment [128–131]. In 2016, the Food and Drug Administration (FDA) labeled FMT as an Investigational New Drug, and they are now considering it an experimental therapy in IBD [130–132].

Preliminary reports of studies that have used FMT in patients with UC or CD have shown promising results regarding the obtaining and maintenance of long-term clinical remission in many cases [133,134]. The profound impairment of the intestinal microbiota among these patients could represent the pathophysiological explanation of the effectiveness of FMT in patients with IBD [133,134].

A recent meta-analysis evaluated 122 patients with IBD who received a FMT (79 with UC, 39 with CD, and 4 with unclassified IBD) and showed a remission rate of 36.2% [135]. The benefits were higher in young patients, especially in the age group 7–20 years. The remission rate was also higher in patients with CD compared to patients with UC (60.5%
vs. 22%) [135]. Equivocal results were obtained in other studies that followed a number of RCTs conducted to quantify the FMT efficacy in UC alone [136–138].

There have been a number of other studies conducted in both adults and children with IBD with controversial results. For example, one study looked at the effectiveness of FMT administered via the nasojejunal tube in patients with moderate or severe forms of UC. After 12 weeks of administration, only one patient showed an improvement in the Mayo Score [139]. Suskind et al. looked at the effectiveness of administering a single FMT via nasogastric tube to four children. Their study did not observe any clinical benefit of FMT [140]. However, Kunde et al. demonstrated significant benefits of FMT when administered via enema. They monitored nine children with UC who received FMT via enema, in one session per day, for five consecutive days [141]. Another study that included 15 adults with steroid-dependent UC showed benefits of performing FMT via upper endoscopy. Of these, eight patients (57%) showed clinical improvement, and four patients remained in remission for a long time [142].

FMT has been shown to be effective in CD in a number of studies. The increase in the diversity of the intestinal microbiota represents the pathophysiological hypothesis of the benefits of FMT among patients with CD. He et al. followed the evolution of 25 patients with CD and an inflammatory mass after performing a FMT. Of these, 13 (52%) obtained clinical remission three months after the FMT. These patients were subsequently evaluated at 6, 12, and 18 months, with the following results: maintenance of clinical remission was reported in 12 of the patients (52%) at 6 months, in 8 of the patients (32%) at 12 months, and in 5 of the patients (22.7%) at 18 months. Cui et al. also reported an improvement in the clinical remission rates of CD patients who underwent FMT. They followed 30 patients with refractory CD. One month after FMT, 86.7% of patients showed clinical response, with a remission rate of 76.7% [143]. Previous published studies reported that another concern related to FMT is considered the risk of an IBD flare (up to 25% with flares), but recent results suggest a much lower risk [144,145].

Although the results of studies to date are variable, FMT may have benefits in the evolution of patients with IBD. The main pathophysiological effect of this therapeutic method in patients with IBD is the amelioration of intestinal dysbiosis. At present, however, it is not known whether intestinal dysbiosis is a primary or secondary event in the evolution of IBD, and, consequently, the impact of dysbiosis correction on the disease remains unclear. Another concern with FMT is the risk of an IBD flare. Early studies reported up to 25% with flares; however recent data suggest a much lower risk. However, it has been observed that patients who underwent FMT showed a clinical and endoscopic improvement compared to those treated with placebo, suggesting the therapeutic potential of this method [146,147].

6. Natural Chemical Compounds in IBD Treatment

Dietary polyphenols are recognized as natural-origin chemical compounds that are included in food products like cereals, fruits [148], vegetables, wine [149–151], dark chocolate (cocoa powder), tea and coffee, and so on. From the chemical point of view, these substances are considered an extended heterogeneous group of compounds, having structural units (phenolic or hydroxylated aromatic rings) in common, in all the phenolic derivatives. Phenolic compounds are classified taking into account the number of phenolic rings they contain in their structure, as well as the structural connecting elements between these rings. The main classes of polyphenols (considered dietary) can be listed as follows: phenolic acids, flavonoids, stilbenes, tannins, and diferuloylmethanes [152,153]—their actions and effects on human health (through the diet) being induced by their chemical structure [154].

Phenolic acids contain a carboxylic function linked to a phenol ring, which is classified in benzoic acid derivatives (ie gallic or protocatechuic acids) and cinnamic acid derivatives (i.e., caffieic, p-coumaric, and ferulic acids) [149].

Stilbenes are organic compounds of hydrocarbons, having in their molecule a trans-ethene double bond, which is replaced by a phenyl group (on both atoms of carbon linked by the double bond) [67]. They can be found in lower quantity in plants, more abundant in
the form of resveratrol and its isomer (trans-resveratrol), and more frequently in grapes and wine [155]. Flavonoids are represented by >10,000 natural chemical compounds, present in about 9000 species of plants [152,153,156], encompassing a wide diversity in their structures; however, they are derived from a common biosynthetic pathway—that is, the phenylpropanoid metabolic pathway, which comprises of the acetate-malonate and shikimic acid pathway precursors—and lead, for example, to kaempferol, quercetin, luteolin, (epi)catechin, (epi)gallocatechin, and so on.

Tannins are defined as polyphenolic organic compounds with the property of precipitating the proteins (especially the salivary proteins) and providing them an astringent character. These characteristics may explain the tannins’ protective role (against pathogens and herbivores) in plants. From the point of view of physical properties, these polyphenols with high molecular weight (between 500–3000 Da) are water-soluble, being classified in two groups: proanthocyanidins (or condensed tannins which are polymers of flavan-3-ol units) and hydrolysable tannins (which are esters formed between phenolic acids and a molecule of cyclic polyalcohol, frequently glucose).

A group of phenolic compounds, Diferuloylmethanes is a class that includes curcumin, which is a commonly known compound, derived mainly from the turmeric spice [156].

Phytochemicals include an extensive variety of natural compounds derived from plants, and have been reported to exert numerous benefits in several chronic disorders, as per multiple pieces of evidence [157]. The gut microbiota and immunity of the intestine has been reported to be influenced by a number of polyphenols, such as flavonoids, phenolic acids, stilbenes, and lignans, which have numerous biological benefits (antioxidant, anticancer, anti-inflammatory, etc.) also presented by hydrophobic polyphenolic derivative of Curcuma longa (i.e., curcumin) [158]. The production of cytokines by macrophages and epithelial cells of the intestine is suppressed by blockage of activation of NF-Kb, therefore abbreviating colitis induced by DSS- and TNBS [159–162].

The polyphenolic compounds present in the diet exhibit limited bioavailability profiles, due to inefficient intestinal absorption of curcumin [162], following which, a large amount of unabsorbed polyphenolic compounds are transported to the large intestine, resulting in their interaction with the gut microbiome of the colon, which further possesses the ability to catabolize polyphenols and degrade them into small fragments [163].

The E. coli-derived curcumin-converting enzyme aids the conversion of curcumin into tetrahydro curcumin [164], which prevent colitis and related colon cancer in mice. A significant involvement of polyphenols in CD has been reported by recent epidemiological study. Furthermore, supplements of curcumin have been reported to exert effective outcomes in the induction and maintenance of remission in UC patients, as per clinical studies [165–168].

However, a very low number of clinical investigations which have directly targeted IBD are available with respect to polyphenol intervention. The investigations, on a general basis, have administered approximately 2 g/d red wine, curcumin, apple, cacao, pycnogenol, and blueberries to the subjects (10 per group), for a period from four weeks to two years. Unfortunately, there are only a very limited number of human trials available that have focused directly on IBD with respect to polyphenol intervention. Chiba et al. conducted a clinical study with 22 CD subjects, and reported maintenance of remission for over two years, by a plant-food-rich semi-vegetarian diet, which was therefore high in polyphenols, unlike an omnivorous diet [169].

Hanai et al. incorporated 2 g of curcumin plus medication per day for over six months to 89 UC patients in a randomized, double-blind, placebo-controlled multicenter intervention study, resulting in potential improvement in UC-associated morbidity parameters (endoscopic and clinical activity index) and recurrence rate [167]. Additionally, besides exerting direct effects, curcumin was also reported to elevate the bioavailability profile of the prescribed medication, via interaction with multiple efflux pumps and/or altered metabolism of phase I/phase II reactions [170].
Koláček et al. conducted a study to investigate the consequences of pycnogenol (i.e., a polyphenolic compound derived from the bark of maritime pine (Pinus pinaster)), comprising procyanidins (70%) at 2 mg/kg BW, on 15 CD patients in remission, for over 10 weeks, where the results were compared to 15 healthy control subjects. However, an accurate comparison was not permitted between the two groups, as the controls were not treated. Elevated concentration of Cu/Zn superoxide dismutase (SOD) was reported in CD patients, as well as enhanced oxidative damage of proteins, unlike in healthy subjects. Inflammatory markers, like calprotectin (i.e., a systemic inflammation-associated protein produced by neutrophils) and CRP were negatively related to the total plasma antioxidant activity (TAC). Following intervention, no significant alteration was reported in most parameters, like F2-isoprostanes, CRP, and reduced glutathione (GSH), as compared to before intervention, whereas levels of lipo-peroxide AOPP were greatly retarded, along with significant elevation in SOD, following intervention. Therefore, unlike inflammatory markers, a significant reduction in oxidative stress markers was reported, making this the first study to investigate the direct actions of hydrophilic polyphenols on IBD patients [171].

Short-term intervention studies have also been conducted, although with rather more contentious results, in part as possible alterations in the inflammation processes during short-term trials. However, in a placebo-controlled study, pain and discomfort in the stomach was abbreviated in children with gastroenterological irritation administered a single dose of a novel prebiotic based upon polyphenols (i.e., 2 ounces of Preliva (Goodgut INC, USA)) rich in Japanese honeysuckle, grape, and pomegranate, unlike the placebo group, without measurement of bacterial cultures and dosage reporting. Furthermore, there is a requirement for more such investigations, preferably with mid-to-long-term polyphenol administration [172].

7. Conclusions

In recent years, the importance of intestinal microflora in maintaining the normal functioning of the body has been more and more recognized. Numerous studies have looked at the potential therapeutic effects of the microorganisms that make up the intestinal microbiome in various diseases.

In IBD, therapies based on the intestinal microbiota have demonstrated great therapeutic potential. According to existing data, the benefits of these therapies can be mainly explained by the immunomodulatory effect. Compared to immunosuppressive treatments, the toxicity is much lower. The aim is to identify therapies based on the intestinal microbiome that can be used not only as adjuvants of immunosuppressive therapies, but also as therapies themselves. Moreover, there are data that suggest the potential of probiotics to reduce the risk of developing the disease among high-risk patients, such as those with a hereditary history of IBD [146].

The use of probiotic agents, especially those of the Lactobacillus and Bifidobacterium species, were reported to be effective in UC, which is why it represents an adjunctive treatment among these patients. Both the improvement of clinical signs and symptoms and the induction/maintenance of the remission period are the main proven benefits of probiotic agents in patients with UC. The mechanisms behind these results are the immunomodulatory and anti-inflammatory effects of probiotic agents. In other words, these products reduce the synthesis of pro-inflammatory mediators and increase the synthesis of anti-inflammatory mediators. Although these effects are potentially present in patients with CD, there are still insufficient data to support the use of probiotics as an adjunctive treatment in patients with CD [65].

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.
**Acknowledgments:** The authors thank to the University of Oradea considering the logistic facilities they used.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Kappelman, M.D.; Rifas-Shiman, S.L.; Porter, C.Q.; Ollendorf, D.A.; Sandler, R.S.; Galanko, J.A.; Finkelstein, J.A. Direct health care costs of Crohn’s disease and ulcerative colitis in US children and adults. *Gastroenterology* 2008, 135, 1907–1913. [CrossRef]

2. Dmochowska, N.; Wardill, H.R.; Hughes, P.A. Advances in imaging specific mediators of inflammatory bowel disease. *Int. J. Mol. Sci.* 2018, 19, 2471. [CrossRef]

3. Su, H.J.; Chiu, Y.T.; Chiu, C.T.; Lin, Y.C.; Wang, C.Y.; Hsieh, J.Y.; Wei, S.C. Inflammatory bowel disease and its treatment in 2018: Global and Taiwanese status updates. *J. Formos. Med. Assoc.* 2019, 118, 1083–1092. [CrossRef] [PubMed]

4. Sturm, A.; Maaser, C.; Calabrese, E.; Annese, V.; Fiorino, G.; Kucharzik, T.; Vavricka, S.R.; Verstockt, B.; van Rheenen, P.; Tolan, D.; et al. Ecco-Esgar Guideline for diagnostic assessment in IBD Part 2: IBD scores and general principles and technical aspects. *J. Crohns Colitis* 2019, 13, 273–284. [CrossRef] [PubMed]

5. Bringiotti, R.; Ierardi, E.; Lovero, R.; Losurdo, G.; Di Leo, A.; Principi, M. Intestinal microbiota: The explosive mixture at the origin of inflammatory bowel disease? *World J. Gastroint. Pathophysiol.* 2014, 5, 550–559. [CrossRef]

6. Sokol, H.; Pigneur, B.; Watterlot, L.; Lakhdari, O.; Bermúdez-Humarín, L.G.; Gratadoux, J.J.; Blugeon, S.; Bramer, E.C.; Harpaz, N.; et al. Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach. *Gut* 2006, 55, 205–211. [CrossRef] [PubMed]

7. Marchesi, J.R.; Seviour, R.; Westcott, S.L.; Torsvik, V.; Grant, P.; Callister, R.T.; Tjander, B.; Woyke, T.; Schmid, T.; et al. A phylogenetic study of the microbial communities in the human large intestine. *ISME J.* 2008, 2, 716–727. [CrossRef] [PubMed]

8. Varela, E.; Manichanh, C.; Gallart, M.; Torrejón, A.; Casellas, F.; Guarner, F.; Antolin, M. Colonisation by Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of endoscopic brush samples identified mucosa-associated dysbiosis in inflammatory bowel disease. *Aliment. Pharmacol. Ther.* 2013, 38, 550–559. [CrossRef] [PubMed]

9. Gourley, S.; Pigneur, B.; Watterlot, L.; Lacroix, H.; Gueguen, E.; Roux, P.; Collard, R.; Westcott, S.L.; Torsvik, V.; Callister, R.T.; et al. Analysis of endoscopic brush samples identified mucosa-associated dysbiosis in inflammatory bowel disease. *Cell Host Microbe* 2014, 15, 382–392. [CrossRef] [PubMed]

10. Fujimoto, T.; Imaeda, H.; Takahashi, K.; Kasumi, E.; Bamba, S.; Fujimura, Y.; Andoh, A. Decreased abundance of Faecalibacterium prausnitzii in the gut microbiota of patients with inflammatory bowel disease. *Cell Host Microbe* 2013, 28, 613–619. [CrossRef] [PubMed]

11. Takahashi, K.; Nishida, A.; Fujimoto, T.; Fujiyama, Y.; Shiyoa, M.; Inami, O.; Sugiimoto, M.; Kawahara, M.; et al. Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach. *Gut* 2006, 55, 205–211. [CrossRef] [PubMed]

12. Dicksved, J.; Halfvarson, J.; Rosenquist, M.; Järnerot, G.; Tysk, C.; Apajalahti, J.; Engstrand, L.; Jansson, J.K. Molecular analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease. *BMC Microbiol.* 2011, 11, 7. [CrossRef] [PubMed]

13. Hsu, J.; Chiu, Y.T.; Chiu, C.T.; Lin, Y.C.; Wang, C.Y.; Hsieh, J.Y.; Wei, S.C.; Yassour, M.; et al. The treatment-naive microbiome in new-onset Crohn's disease. *J. Formos. Med. Assoc.* 2013, 112, 95–106. [CrossRef] [PubMed]

14. Kappelman, M.D.; Rifas-Shiman, S.L.; Porter, C.Q.; Ollendorf, D.A.; Sandler, R.S.; Galanko, J.A.; Finkelstein, J.A. Direct health care costs of Crohn’s disease and ulcerative colitis in US children and adults. *Gastroenterology* 2008, 135, 1907–1913. [CrossRef]

15. Martínez, C.; Antolin, M.; Santos, J.; Torrejón, A.; Casellas, F.; Bamba, S.; Fujiyama, Y.; Andoh, A. Decreased abundance of butyrate-producing bacteria species in the fecal microbial community in inflammatory bowel disease. *J. Gastroenterol. Hepatol.* 2007, 22, 1083–1092. [CrossRef] [PubMed]

16. Okita, T.; Kanda, T.; Nakajima, T.; Kamata, T.; Inoue, M.; Yamaoka, Y.; Shiyoa, M.; et al. Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach. *Gut* 2006, 55, 205–211. [CrossRef] [PubMed]

17. Halfvarson, J.; Lamendella, R.; Vázquez-Baeza, Y.; Walters, W.A.; Brumer, L.M.; D’Amato, M.; Bonfiglio, F.; McDonald, D.; Gonzalez, A.; et al. Dynamics of the human gut microbiome in inflammatory bowel disease. *Nat. Microbiol.* 2017, 2, 17004. [CrossRef] [PubMed]

18. Morgan, X.C.; Tickle, T.L.; Sokol, H.; Gevers, D.; Devaney, K.L.; Ward, D.V.; Reeyes, J.A.; Shah, S.A.; LeLeiko, N.; Snapper, S.B.; et al. Dysfunction of the intestinal microbiota in inflammatory bowel disease and treatment. *Genome Biol.* 2012, 13, R79. [CrossRef] [PubMed]

19. Frank, D.N.; St Amand, A.L.; Feldman, R.A.; Boedeker, E.C.; Harpaz, N.; Pace, N.R. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. *Proc. Natl. Acad. Sci. USA* 2007, 104, 13780–13785. [CrossRef] [PubMed]

20. Walker, A.W.; Sanderson, J.D.; Churcher, C.; Parkes, G.C.; Hudspith, B.N.; Rayment, N.; Brostoff, J.; Parkhill, J.; Dougan, G.; Petrovska, L. High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease. *BMC Microbiol.* 2011, 11, 7. [CrossRef] [PubMed]

21. Hansen, J.; Gulati, A.; Sartor, R.B. The role of mucosal immunity and host genetics in defining intestinal commensal bacteria. *Curr. Opin. Gastroenterol.* 2010, 26, 564–571. [CrossRef] [PubMed]

22. Varela, E.; Manichanh, C.; Gallart, M.; Torrejón, A.; Bamba, S.; Casellas, F.; Guarnier, F.; Antolin, M. Colonisation by Faecalibacterium prausnitzii and maintenance of clinical remission in patients with ulcerative colitis. *World J. Gastrointest. Pathophysiol.* 2013, 4, 1090. [CrossRef] [PubMed]

23. Okita, T.; Kanda, T.; Nakajima, T.; Kamata, T.; Inoue, M.; Yamaoka, Y.; Shiyoa, M.; et al. Analysis of inflammatory bowel diseases. *Cell Host Microbe* 2014, 15, 382–392. [CrossRef] [PubMed]

24. Okita, T.; Kanda, T.; Nakajima, T.; Kamata, T.; Inoue, M.; Yamaoka, Y.; Shiyoa, M.; et al. Analysis of endoscopic brush samples identified mucosa-associated dysbiosis in inflammatory bowel disease. *J. Gastroenterol.* 2018, 53, 95–106. [CrossRef] [PubMed]

25. Peterson, D.A.; Frank, D.N.; Pace, N.R.; Gordon, J.I. Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases. *Cell Host Microbe* 2008, 3, 417–427. [CrossRef] [PubMed]
24. Darfeuille-Michaud, A.; Boudeau, J.; Bullois, P.; Neut, C.; Glasser, A.L.; Barnich, N.; Bringer, M.A.; Swidsinski, A.; Beaucher, L.; Colombel, J.F. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn’s disease. Gastroenterology 2004, 127, 412–421. [CrossRef]
25. El Asmar, R.; Panigrahi, P.; Bamford, P.; Berti, I.; Not, T.; Coppa, G.V.; Catassi, C.; Fasano, A. Host-dependent zonulin secretion causes the impairment of the small intestine barrier function after bacterial exposure. Gastroenterology 2002, 123, 1607–1615. [CrossRef][PubMed]
26. Arrieta, M.C.; Madsen, K.; Doyle, J.; Meddings, J. Reducing small intestinal permeability attenuates colitis in the IL10 gene-deficient mouse. Gut 2019, 58, 41. [CrossRef]
27. Caviglia, G.P.; Dughera, F.; Ribaldone, D.G.; Rosso, C.; Abate, M.L.; Pellicano, R.; Bresso, F.; Smedile, A.; Saracco, G.M.; Astegiano, G. The gut microbiota in the pathogenesis and therapeutics of inflammatory bowel disease. Front. Microbiol. 2018, 9, 2247. [CrossRef]
28. Atarashi, K.; Tonaue, T.; Oshima, K.; Suda, W.; Nishikawa, H.; Fukuda, S.; Saito, T.; Narushima, S.; Hase, K.; et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature 2013, 500, 232–236. [CrossRef][PubMed]
29. Zuo, T.; Ng, S.C. The gut microbiota in the pathogenesis and therapeutics of inflammatory bowel disease. Front. Microbiol. 2018, 9, 2247. [CrossRef]
30. Lupp, C.; Robertson, M.L.; Wickham, M.E.; Sekirov, I.; Champion, O.L.; Gaynor, E.C.; Finlay, B.B. Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae. Cell Host Microbe 2007, 2, 119–129. [CrossRef]
31. Sokol, H.; Seksik, P.; Furet, J.P.; Firmesse, O.; Nion-Larmurier, I.; Beauger, L.; Cosnes, J.; Corthier, G.; Marteau, P.; Doré, J. Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm. Bowel Dis. 2009, 15, 1183–1189. [CrossRef][PubMed]
32. Ohkusa, T.; Yoshida, T.; Sato, N.; Watanabe, S.; Tajiri, H.; Okayasu, I. Commensal bacteria can enter colonic epithelial cells and induce proinflammatory cytokine secretion: A possible pathogenic mechanism of ulcerative colitis. J. Med. Microbiol. 2009, 58, 535–545. [CrossRef]
33. Yu, T.; Guo, F.; Yu, Y.; Sun, T.; Ma, D.; Han, J.; Qian, Y.; Kryczek, I.; Sun, D.; Nagarsheth, N.; et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell 2017, 170, 548–563.e516. [CrossRef][PubMed]
34. Kostic, A.D.; Chun, E.; Robertson, M.L.; Gallini, C.A.; Podolsky, D.K. Functional modulation of enterocytes by gram-positive and gram-negative microorganisms. Gastroenterology 2012, 142, 177–186. [CrossRef][PubMed]
35. Willing, B.; Halfvarson, J.; Dicksev, J.; Rosenquist, M.; Järnerot, G.; Engstrand, L.; Tysk, C.; Jansson, J.K. Twin studies reveal specific imbalances in the mucosa-associated microbiota of patients with ileal Crohn’s disease. Inflamm. Bowel Dis. 2009, 15, 653–660. [CrossRef]
36. Papamichael, K.; Konstantopoulo, P.; Mantzaris, G.J. Helicobacter pylori infection and inflammatory bowel disease: Is there a link? World J. Gastroenterol. 2014, 20, 6374–6385. [CrossRef]
37. Mora, D.; Filardi, R.; Arioli, S.; Boeren, S.; Aalvink, S.; de Vos, W.M. Development of omics-based protocols for the microbiological characterization of multi-strain formulations marketed as probiotics: The case of VSL#3. Microbiome 2019, 12, 1371–1386. [CrossRef]
38. Silva, N.O.; de Brito, B.B.; da Silva, F.A.F.; Santos, M.L.C.; de Melo, F.F. Probiotics in inflammatory bowel disease: Does it work? Front. Microbiol. 2020, 11, 54–66. [CrossRef]
39. Nerstedt, A.; Nilsson, E.C.; Ohlson, K.; Håkansson, J.; Thomas Svensson, L.; Löwenadler, B.; Svensson, U.K.; Mahlapuu, M. Administration of Lactobacillus gasseri S-105, a newly discovered bacteria that promotes chemoresistance to colorectal cancer by modulating autophagy. Inflamm. Bowel Dis. 2019, 25, 1670–1677. [CrossRef][PubMed]
40. Darfeuille-Michaud, A.; Boudeau, J.; Bullois, P.; Neut, C.; Glasser, A.L.; Barnich, N.; Bringer, M.A.; Swidsinski, A.; Beaucher, L.; Colombel, J.F. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn’s disease. Gastroenterology 2004, 127, 412–421. [CrossRef]
41. Arora, A.; Behl, T.; Sehgal, A.; Singh, S.; Sharma, N.; Bhagat, S.; Sobotar-Sanchez, E.; Bungau, S. Unravelling the involvement of gut microbiota in type 2 diabetes mellitus. Life Sci. 2021, 1090, 412–421. [CrossRef]
42. Neish, A.S. Bacterial inhibition of eukaryotic pro-inflammatory pathways. Immunol. Rev. 2004, 202, 250–265. [CrossRef]
50. Aureli, P.; Capurso, L.; Castellazzi, A.M.; Clerici, M.; Giovannini, M.; Morelli, L.; Poli, A.; Pregliasco, F.; Salvini, F.; Zuccotti, G.V. Probiotics and health: An evidence-based review. *Pharmacol. Res.* 2011, 63, 366–376. [CrossRef] [PubMed]

51. Gómez-Lorente, C.; Muñoz, S.; Gil, A. Role of Toll-like receptors in the development of immunotolerance mediated by probiotics. *Proc. Nutr. Soc.* 2010, 69, 381–389. [CrossRef]

52. Rizzello, V.; Bonaccorsi, I.; Dongarrá, M.L.; Fink, L.N.; Ferlazzo, G. Role of natural killer and dendritic cell cross-talk in immunomodulation by commensal bacteria probiotics. *J. Biomed. Biotechnol.* 2011, 473097. [CrossRef]

53. Cain, A.M.; Karpa, K.D. Clinical utility of probiotics in inflammatory bowel disease. *Altern. Ther. Health Med.* 2011, 17, 72–79. [PubMed]

54. Damaskos, D.; Kolios, G. Probiotics and prebiotics in inflammatory bowel disease: Microflora 'on the scope'. *Br. J. Clin. Pharmacol.* 2008, 65, 453–467. [CrossRef]

55. Guslandi, M.; Mezzi, G.; Sorghi, M.; Testoni, P.A. Saccharomyces boulardii in maintenance treatment of Crohn’s disease. *Dig. Dis. Sci.* 2000, 45, 1462–1464. [CrossRef] [PubMed]

56. Bourreille, A.; Cadiot, G.; Le Dreau, G.; Laharie, D.; Beaugerie, L.; Dupas, J.L.; Marteau, P.; Rampal, P.; Moyse, D.; Saleh, A.; et al. Saccharomyces boulardii does not prevent relapse of Crohn’s disease. *Clin. Gastroenterol. Hepatol.* 2013, 11, 982–987. [CrossRef]

57. Generoso, S.V.; Viana, M.L.; Santos, R.G.; Arantes, R.M.; Martins, F.S.; Nicolli, J.R.; Machado, J.A.; Correia, M.I.; Cardoso, V.N. Protection against increased intestinal permeability and bacterial translocation induced by intestinal obstruction in mice treated with viable and heat-killed Saccharomyces boulardii. *Eur. J. Nutr.* 2011, 50, 261–269. [CrossRef]

58. Steed, H.; Macfarlane, G.T.; Blackett, K.L.; Bahrami, B.; Reynolds, N.; Walsh, S.V.; Cummings, J.H.; Macfarlane, G.T. Clinical trial: The microbiological and immunological effects of symbiotic probiotics and prebiotics cotherapy for remission induction of active Crohn’s disease. *Clin. Gastroenterol. Hepatol.* 2015, 13, 928–935.e922. [CrossRef] [PubMed]

59. Gupta, P.; Andrew, H.; Kirscher, B.S.; Guandalini, S. Is lactobacillus GG helpful in children with Crohn’s disease? Results of a preliminary, open-label study. *J. Pediatr. Gastroenterol. Nutr.* 2000, 31, 453–457. [CrossRef] [PubMed]

60. Sood, A.; Midha, V.; Makharia, G.K.; Ahuja, V.; Singal, D.; Goswami, P.; Tandon, R.K. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderate active ulcerative colitis. *Clin. Gastroenterol. Hepatol.* 2009, 7, 1202–1209.e1201. [CrossRef] [PubMed]

61. Miele, E.; Pascarella, F.; Giannetti, E.; Quaglietta, L.; Baldassano, R.N.; Staiano, A. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. *Am. J. Gastroenterol.* 2009, 104, 437–443. [CrossRef]

62. Huyhn, H.Q.; deBruyn, J.; Guan, L.; Diaz, H.; Li, M.; Girgis, S.; Turner, J.; Fedorak, R.; Madsen, K. Probiotic preparation VSL#3 induces remission in children with mild to moderate acute ulcerative colitis: A pilot study. *Inflamm. Bowel Dis.* 2009, 15, 760–768. [CrossRef]

63. Petersen, A.M.; Mirsepas, H.; Halkjær, S.I.; Mortensen, E.M.; Nordgaard-Lassen, I.; Krogefalt, K.A. Ciprofloxacin and probiotic Escherichia coli Nissle add-on treatment in active ulcerative colitis: A double-blind randomized placebo controlled clinical trial. *J. Crohns Colitis* 2014, 8, 1498–1505. [CrossRef] [PubMed]
74. Matthes, H.; Krummenerl, T.; Giensch, M.; Wolff, C.; Schulze, J. Clinical trial: Probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN). BMC Complement. Altern. Med. 2010, 10, 13. [CrossRef]

75. Oliva, S.; Di Nardo, G.; Ferrari, F.; Maillardro, S.; Rossi, P.; Patrizi, G.; Cuaciara, S.; Stronati, L. Randomised clinical trial: The effectiveness of Lactobacillus reuterl ATCC 55730 rectal enema in children with active distal ulcerative colitis. Aliment. Pharmacol. Ther. 2012, 35, 327–334. [CrossRef] [PubMed]

76. Shanahan, F.; Collins, S.M. Pharmabiotic manipulation of the microbiota in gastrointestinal disorders, from rationale to reality. Gastroenterol. Clin. N. Am. 2010, 39, 721–726. [CrossRef]

77. Kruis, W.; Schütz, E.; Fric, P.; Fixa, B.; Judmaier, G.; Stolte, M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment. Pharmacol. Ther. 1997, 11, 853–858. [CrossRef] [PubMed]

78. Rembacken, B.J.; Snelling, A.M.; Hawkey, P.M.; Chalmers, D.M.; Axon, A.T. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: A randomised trial. Lancet 1999, 354, 635–639. [CrossRef] [PubMed]

79. Kruis, W.; Fric, P.; Pokrotniaks, J.; Lukás, M.; Fixa, B.; Kascák, M.; Kamm, M.A.; Weismueller, J.; Beglinger, C.; Stolte, M.; et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004, 53, 1617–1623. [CrossRef]

80. Colombel, J.-F.; D’Haens, G.; Lee, W.-J.; Petersson, J.; Panaccione, R. Outcomes and strategies to support a treat-to-target approach in inflammatory bowel disease: A systematic review. J. Crohns Colitis 2010, 14, 254–266. [CrossRef] [PubMed]

81. Guslandi, M. Saccharomyces boulardii plus rifaximin in mesalamine-intolerant ulcerative colitis. Aliment. Pharmacol. Ther. 2003, 17, 1211–1215. [CrossRef] [PubMed]

82. Madsen, K.L.; Doyle, J.S.; Jewell, L.D.; Tavernini, M.M.; Fedorak, R.N. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 1999, 116, 1107–1114. [CrossRef]

83. Osman, N.; Adawi, D.; Ahrne, S.; Jeppsson, B.; Molin, G. Modulation of the effect of dextran sulfate sodium-induced acute inflammation with rectally administered Escherichia coli Nissle 1917 (EcN). Eur. J. Gastroenterol. Hepatol. 2013, 6, 39–51. [CrossRef] [PubMed]

84. Wosinska, L.; Cotter, P.D.; O’Sullivan, O.; Guinane, C. The potential impact of probiotics on the gut microbiome of athletes. Nutrients 2019, 11, 2270. [CrossRef] [PubMed]

85. Malchow, H.A. Crohn’s disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn’s disease? J. Clin. Gastroenterol. 1997, 25, 653–658. [CrossRef]

86. Guslandi, M.; Giolito, P.; Testoni, P.A. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur. J. Gastroenterol. Hepatol. 2003, 15, 697–698. [CrossRef]

87. Furrie, E.; Macfarlane, S.; Kennedy, A.; Cummings, J.H.; Walsh, S.V.; O’Neil, D.A.; Macfarlane, G.T. Symbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: A randomised controlled pilot trial. Gut 2005, 54, 242–249. [CrossRef]

88. Tamaki, H.; Nakase, H.; Itani, T.; Kawanami, C.; Itani, T.; Ohana, M.; Kusaka, T.; Uose, S.; Hisatsune, H.; Tojo, M.; et al. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial. Dig. Endosc. 2016, 28, 67–74. [CrossRef]

89. Ishikawa, H.; Matsumoto, S.; Ohashi, Y.; Imaoka, A.; Setoyama, H.; Umesaki, Y.; Tanaka, R.; Otani, T. Beneficial effects of probiotic bifidobacterium and galacto-oligosaccharide in patients with ulcerative colitis: A randomized controlled study. Digestion 2011, 84, 128–133. [CrossRef] [PubMed]

90. Zocco, M.A.; dal Verme, L.Z.; Cremonini, F.; Piscaglia, A.C.; Nista, E.C.; Candelli, M.; Novi, M.; Rigante, D.; Cazzato, I.A.; Ojetti, V.; et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment. Pharmacol. Ther. 2006, 23, 1567–1574. [CrossRef] [PubMed]

91. Hegazy, S.K.; El-Bedewy, M.M. Effect of probiotics on pro-inflammatory cytokines and NF-kappaB activation in ulcerative colitis. World J. Gastroenterol. 2010, 16, 4145–4151. [CrossRef]

92. Palumbo, V.D.; Romeo, M.; Marino Gammazza, A.; Carini, F.; Damiani, P.; Damiano, G.; Buscemi, S.; Lo Monte, A.L.; Gerges-Geagea, A.; Jurus, A.; et al. The long-term effects of probiotics in the therapy of ulcerative colitis: A clinical study. Biomed. Pap. Med. Fac Univ Palacky Olomouc Czech. Repub 2016, 160, 372–377. [CrossRef]

93. Singh, N.; Gurav, A.; Sivaprakasam, S.; Brady, E.; Padia, R.; Shi, H.; Thangaraju, M.; Prasad, P.D.; Manicassamy, S.; Munn, D.H.; et al. Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity 2014, 40, 128–139. [CrossRef]

94. Arpaia, N.; Campbell, C.; Fan, X.; Dikiy, S.; van der Veen, J.; deRoos, P.; Liu, H.; Cross, J.R.; Pfeffer, K.; Coffer, P.J.; et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 2013, 504, 451–455. [CrossRef] [PubMed]

95. Furušawa, Y.; Obata, Y.; Fukuda, S.; Endo, T.A.; Nakato, G.; Takahashi, D.; Nakanishi, Y.; Uetake, C.; Kato, K.; Kato, T.; et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 2013, 504, 446–450. [CrossRef] [PubMed]

96. Looijer-van Langen, M.A.; Dieleman, L.A. Prebiotics in chronic intestinal inflammation. Inflamm. Bowel Dis. 2009, 15, 454–462. [CrossRef] [PubMed]
98. Verbeke, K.A.; Boesmans, L.; Boets, E. Modulating the microbiota in inflammatory bowel diseases: Prebiotics, probiotics or faecal transplantation? *Proc. Nutr. Soc.* 2014, **73**, 490–497. [CrossRef] [PubMed]

99. Benjamin, J.L.; Hedlin, C.R.; Koutoumpas, A.; Ng, S.C.; McCarthy, N.E.; Hart, A.L.; Kamm, M.A.; Sanderson, J.D.; Knight, S.C.; Forbes, A.; et al. Randomised, double-blind, placebo-controlled trial of fructo-oligo saccharides in active Crohn’s disease. *Gut* **2011**, **60**, 923–929. [CrossRef]

100. Casellas, F.; Borruel, N.; Torrejón, A.; Varela, E.; Antolin, M.; Guarner, F.; Malagelada, J.R. Oral oligofructose-enriched inulin supplementation in acute ulcerative colitis is well tolerated and associated with lowered faecal calprotectin. *Aliment. Pharmacol. Ther.* **2007**, **25**, 1061–1067. [CrossRef]

101. Chermesh, I.; Tamir, A.; Reshef, R.; Chowers, Y.; Suissa, A.; Katz, D.; Gelber, M.; Halpern, Z.; Eliaikim, R. Failure of Symbiotic 2000 to prevent postoperative recurrence of Crohn’s disease. *Dig. Dis. Sci.* **2007**, **52**, 385–389. [CrossRef]

102. Wélters, C.F.; Heineman, E.; Thunnissen, F.B.; van den Bogaard, A.E.; Soeters, P.B.; Baeten, C.G. Effect of dietary inulin supplementation on inflammation of pouch mucosa in patients with an ileal pouch-anal anastomosis. *Dis. Colon Rectum* **2002**, **45**, 621–627. [CrossRef]

103. Dewulf, E.M.; Cani, P.D.; Claas, S.P.; Fuentes, S.; Puylaert, P.G.; Neyrinck, A.M.; Bindels, L.B.; de Vos, W.M.; Gibson, G.R.; Thiessen, J.P.; et al. Insight into the prebiotic concept: Lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women. *Gut* **2013**, **62**, 1112–1121. [CrossRef]

104. Ramirez-Farias, C.; Slezk, K.; Fuller, Z.; Duncan, A.; Holtrop, G.; Louis, P. Effect of inulin on the human gut microbiota: Stimulation of Bifidobacterium adolescentis and Faecalibacterium prausnitzii. *Br. J. Nutr.* **2009**, **101**, 541–550. [CrossRef]

105. Vandeputte, D.; Falony, G.; Vieira-Silva, S.; Wang, J.; Sailer, M.; Theis, S.; Verbeke, K.; Raes, J. Prebiotic inulin-type fructans induce specific changes in the human gut microbiota. *Gut* **2017**, **66**, 1968–1974. [CrossRef] [PubMed]

106. Riviére, A.; Selak, M.; Lantin, D.; Leroy, F.; De Vuyyst, L. Bifidobacteria and butyrate-producing colon bacteria: Importance and strategies for their stimulation in the human gut. *Front. Microbiol.* **2016**, **7**, 979. [CrossRef] [PubMed]

107. Bouhnik, Y.; Vahedi, K.; Achour, L.; Attar, A.; Salfati, J.; Pochart, P.; Marteau, P.; Flouri, A.;109; et al. Insight into the prebiotic concept: Lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women. *Gut* **2013**, 62, 1112–1121. [CrossRef]

108. Bouhnik, Y.; Raskine, L.; Simonneau, G.; Paineau, D.; Borne, F. The capacity of short-chain fructo-oligosaccharides to stimulate faecal bifidobacteria: A dose-response relationship study in healthy humans. *Nutr. J.* **2006**, **5**, 8. [CrossRef]

109. Gibson, G.R.; Beatty, E.R.; Wang, X.; Cummings, J.H. Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin. *Gastroenterology* **1995**, **108**, 975–982. [CrossRef]

110. Hiel, S.; Bindels, L.B.; Pachikian, B.D.; Kalala, G.; Broers, V.; Zamariola, G.; Chang, B.P.I.; Kambashi, B.; Rodriguez, J.; Cani, P.D.; et al. Effects of a diet based on inulin-rich vegetables on gut health and nutritional behavior in healthy humans. *Am. J. Clin. Nutr.* **2019**, **109**, 1683–1695. [CrossRef] [PubMed]

111. Ramman, P.; Gaudier, E.; Bingham, M.; van Bruggen, P.; Tuohy, K.M.; Gibson, G.R. Prebiotic effect of fruit and vegetable shots containing Jerusalem artichoke inulin: A human intervention study. *Br. J. Nutr.* **2010**, **104**, 233–240. [CrossRef]

112. Kleessen, B.; Schwarz, S.; Boehm, A.; Fuhrmann, H.; Richter, A.; Henle, T.; Krueger, M. Jerusalem artichoke and chicory inulin in bakery products affect faecal microflora of healthy volunteers. *Br. J. Nutr.* **2007**, **98**, 540–549. [CrossRef]

113. Carotti, S.; Gharani, M.P.; Vespasiani-Gentilucci, U.; Morini, S. Starring role of toll-like receptor-4 activation in the gut-liver axis. *Anaerobe* **2019**, **59**, 108–116. [CrossRef] [PubMed]

114. Tuohy, K.M.; Ziemer, C.; Klinker, K.; Knöbel, Y.; Pool-Zobel, B.L.; Gibson, G.R. A human volunteer study to determine the prebiotic effects of lactulose powder on human colonic microbiota. *Microbiol. Ecol. Health Dis.* **2010**, **21**, 165–173. [CrossRef]

115. Bothe, M.K.; Maathuis, A.J.H.; Bellmann, S.; van der Vossen, J.; Berressem, D.; Koehler, A.; Schwejda-Guettes, S.; Gaigg, B.; Kuchinka-Koch, A.; Stover, J.F. Dose-dependent prebiotic effect of lactulose in a computer-controlled in vitro model of the human large intestine. *Nutrients* **2017**, **9**, 767. [CrossRef] [PubMed]

116. Sakai, Y.; Seki, N.; Hamano, H.; Ochi, H.; Abe, F.; Shimizu, F.; Masuda, K.; Iino, H. A study of the prebiotic effect of lactulose at low dosages in healthy Japanese women. *Biosci. Microbiota Food Health* **2019**, **38**, 69–72. [CrossRef] [PubMed]

117. Ruszkowski, J.; Witkowski, J.M. Lactulose: Patient- and dose-dependent prebiotic properties in humans. *Anaerobe* **2019**, **59**, 100–106. [CrossRef]

118. Leefr, J.M.; Dépeint, F.; Clerc, E.; Dugnet, Y.; Niamba, C.N.; Rhazi, L.; Ceyzeele, A.; Abdelnour, G.; Jaruga, A.; Younes, H.; et al. Xylo-oligosaccharide (XOS) in combination with inulin modulates both the intestinal environment and immune status in healthy subjects, while XOS alone only shows prebiotic properties. *Br. J. Nutr.* **2012**, **108**, 1847–1858. [CrossRef]

119. Mäkeläinen, H.; Saarinen, M.; Stowell, J.; Rautonen, N.; Ouwehand, A.C. Xylo-oligosaccharides and lactitol promote the growth of Bifidobacterium lactis and Lactobacillus species in pure cultures. *Benef. Microbes* **2010**, **1**, 139–148. [CrossRef] [PubMed]

120. Mäkeläinen, H.; Forsten, S.; Saarinen, M.; Stowell, J.; Rautonen, N.; Ouwehand, A.C. Xylo-oligosaccharides enhance the growth of bifidobacteria and Bifidobacterium lactis in a simulated colon model. *Benef. Microbes* **2010**, **1**, 81–91. [CrossRef]

121. Lin, S.H.; Chou, L.M.; Chien, Y.W.; Chang, J.S.; Lin, C.I. Prebiotic effects of xylooligosaccharides on the improvement of microbiota balance in human subjects. *Gastroenterol. Res. Pract.* **2016**, **2016**, 5789232. [CrossRef] [PubMed]

122. Finegold, S.M.; Li, Z.; Summanen, P.H.; Downes, J.; Thomas, G.; Corbett, K.; Dowd, S.; Krak, M.; Beber, D. Xylooligosaccharide increases bifidobacteria but not lactobacilli in human gut microbiota. *Food Funct.* **2014**, **5**, 436–445. [CrossRef] [PubMed]
123. Švejstil, R.; Musilová, Š.; Rada, V. Raffinose-series oligosaccharides in soybean products. *Sci. Agric. Bohem.* 2015, 46, 73–77. [CrossRef]

124. Pérez-López, E.; Cela, D.; Costabile, A.; Mateos-Aparicio, I.; Rupérez, P. In vitro fermentability and prebiotic potential of soybean Okara by human faecal microbiota. *Br. J. Nutr.* 2016, 116, 1116–1124. [CrossRef] [PubMed]

125. Ma, Y.; Wu, X.; Giovannini, V.; Meng, X. Effects of soybean oligosaccharides on intestinal microbial communities and immune modulation in mice. *Saudi J. Biol. Sci.* 2017, 24, 114–121. [CrossRef] [PubMed]

126. Shen, Z.H.; Zhu, C.X.; Quan, Y.S.; Yang, Z.Y.; Wu, S.; Luo, W.W.; Tan, B.; Wang, X.Y. Relationship between intestinal microbiota and ulcerative colitis: Mechanisms and clinical application of probiotics and fecal microbiota transplantation. *World J. Gastroenterol.* 2018, 24, 5–14. [CrossRef]

127. Burrello, C.; Garavaglia, F.; Cribù, F.M.; Ercoli, G.; Lopez, G.; Troisi, J.; Colucci, A.; Guglietta, S.; Carloni, S.; Guglielmetti, S. Therapeutic faecal microbiota transplantation controls intestinal inflammation through IL10 secretion by immune cells. *Nat. Commun.* 2018, 9, 1–17. [CrossRef]

128. Austin, M.; Mellow, M.; Tierney, W.M. Fecal microbiota transplantation in the treatment of *Clostridium* difficile infections. *Am. J. Med.* 2014, 127, 479–483. [CrossRef]

129. Cammarota, G.; Masucci, L.; Ianio, G.; Bibbò, S.; Dinoi, G.; Costamagna, G.; Sanguinetti, M.; Gasbarrini, A. Randomised clinical trial: Faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent *Clostridium difficile* infection. *Aliment. Pharmacol. Ther.* 2015, 41, 835–843. [CrossRef]

130. Kassam, Z.; Lee, C.H.; Yuan, Y.; Hunt, R.H. Fecal microbiota transplantation for *Clostridium difficile* infection: Systematic review and meta-analysis. *Am. J. Gastroenterol.* 2013, 108, 500–508. [CrossRef]

131. Kelly, C.R.; Ihunnah, C.; Fischer, M.; Khoruts, A.; Surawicz, C.; Afzali, A.; Aroniadis, O.; Barto, A.; Borody, T.; Giovanelli, A.; et al. Fecal microbiota transplant for treatment of *Clostridium difficile* infection in immunocompromised patients. *Am. J. Gastroenterol.* 2014, 109, 1065–1071. [CrossRef]

132. Moore, T.; Rodriguez, A.; Bakken, J.S. Fecal microbiota transplantation: A practical update for the infectious disease specialist. *Clin. Infect. Dis.* 2014, 58, 541–545. [CrossRef]

133. Bennet, J.D.; Brinkman, M. Treatment of ulcerative colitis by implantation of normal colonic flora. *Lancet* 1989, 1, 164. [CrossRef]

134. Borody, T.J.; George, L.; Andrews, P.; Brandl, S.; Noonan, S.; Cole, P.; Hyland, L.; Morgan, A.; Maysey, J.; Moore-Jones, D. Bowel-flora alteration: A potential cure for inflammatory bowel disease and irritable bowel syndrome? *Med. J. Aust.* 1989, 150, 604. [CrossRef] [PubMed]

135. Colman, R.J.; Rubin, D.T. Fecal microbiota transplantation as therapy for inflammatory bowel disease: A systematic review and meta-analysis. *J. Crohns Colitis* 2014, 8, 1569–1581. [CrossRef]

136. Moayyedi, P.; Surette, M.G.; Kim, P.T.; Libertucci, J.; Wolfe, M.; Onischi, C.; Armstrong, D.; Marshall, J.K.; Kassam, Z.; Reinisch, W. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. *Gastroenterology* 2015, 149, 102–109. [CrossRef]

137. Rossen, N.G.; Fuentes, S.; van der Spek, M.J.; Tijssen, J.G.; Hartman, J.H.A.; Duflou, A.; Löwenberg, M.; van den Brink, G.R.; Mathus-Vliegen, E.M.H.; de Vos, W.M. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. *Gastroenterology* 2015, 149, 110–118. [CrossRef]

138. Paramsothy, S.; Kamm, M.A.; Kaakoush, N.O.; Walsh, A.J.; van den Bogaerde, J.; Samuel, D.; Leong, R.W.L.; Connor, S.; Ng, W.; Paramsothy, R. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: A randomised placebo-controlled trial. *Lancet* 2017, 389, 1218–1228. [CrossRef]

139. Angelberger, S.; Reinisch, W.; Makristathis, A.; Lichtenberger, C.; Dejaco, C.; Papay, P.; Novacek, G.; Trauner, M.; Loy, A.; Berry, D. Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. *Am. J. Gastroenterol.* 2013, 108, 1620–1630. [CrossRef] [PubMed]

140. Suskind, D.L.; Singh, N.; Nelson, H.; Wahbeh, G. Fecal microbial transplant via nasogastric tube for active pediatric ulcerative colitis. *J. Pediatr. Gastroenterol. Nutr.* 2015, 60, 27–29. [CrossRef]

141. Kunde, S.; Pham, A.; Bonczyk, S.; Crumb, T.; Duba, M.; Conrad, H., Jr.; Cloney, D.; Kugathasan, S. Safety, tolerability, and clinical response after fecal transplantation in children and young adults with ulcerative colitis. *J. Pediatr. Gastroenterol. Nutr.* 2013, 56, 597–601. [CrossRef] [PubMed]

142. Cui, B.; Li, P.; Xu, L.; Zhao, Y.; Wang, H.; Peng, Z.; Xu, H.; Xiang, J.; He, Z.; Zhang, T.; et al. Step-up fecal microbiota transplantation strategy: A pilot study for steroid-dependent ulcerative colitis. *J. Transl. Med.* 2015, 13, 298. [CrossRef] [PubMed]

143. Vaughn, B.P.; Vatanen, T.; Allegretti, J.R.; Bai, A.; Xavier, R.J.; Korzenik, J.; Gevers, D.; Ting, A.; Robson, S.C.; Moss, A.C. Increased intestinal microbial diversity following fecal microbiota transplant for active Crohn’s disease. *Inflamm. Bowel Dis.* 2016, 22, 2182–2190. [CrossRef] [PubMed]

144. Qazi, T.; Amaratunga, T.; Barnes, E.L.; Fischer, M.; Kassam, Z.; Allegretti, J.R. The risk of inflammatory bowel disease flares after fecal microbiota transplantation: Systematic review and meta-analysis. *Gut Microbes* 2017, 8, 574–588. [CrossRef]

145. Khoruts, A.; Rank, K.M.; Newman, K.M.; Viskocil, K.; Vaughn, B.P.; Hamilton, M.J.; Sadowsky, M.J. Inflammatory bowel disease affects the outcome of fecal microbiota transplantation for recurrent *Clostridium difficile* infection. *Clin. Gastroenterol. Hepatol.* 2016, 14, 1433–1438. [CrossRef]

146. Hansen, J.J.; Sartor, R.B. Therapeutic manipulation of the microbiome in IBD: Current results and future approaches. *Curr. Treat. Options Gastroenterol.* 2015, 13, 105–120. [CrossRef]
